Proteomic profiling of follicular and papillary thyroid tumors

European Journal of Endocrinology

Volumn 166, Issue 4, 2012, Pages 657-667

  Sofiadis, Anastasios ^a   Becker, Susanne ^a   Hellman, Ulf ^b   Hultin Rosenberg, Lina ^a   Dinets, Andrii ^a   Hulchiy, Mykola ^c   Zedenius, Jan ^a   Wallin, Göran ^d   Foukakis, Theodoros ^a   Höög, Anders ^a   Auer, Gert ^a   Lehtiö, Janne ^a,e   Larsson, Catharina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c Kyiv City Teaching Endocrinological Center   (Ukraine)

^d ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^e SCIENCE FOR LIFE LABORATORY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA TUBULIN; CYTOPLASM PROTEIN; LIPOCORTIN 5; PEROXIREDOXIN 6; PROTEIN 14 3 3; PROTEIN 14 3 3 ALPHA; PROTEIN 14 3 3 BETA; PROTEIN 14 3 3 DELTA; PROTEIN 14 3 3 EPSILON; PROTEIN 14 3 3 ZETA; PROTEIN DISULFIDE ISOMERASE; PROTEIN PRECURSOR; SELENIUM BINDING PROTEIN; SELENIUM BINDING PROTEIN 1; TUBULIN ALPHA 1B CHAIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADENOMA; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RESEARCH; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSOL; FROZEN SECTION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MOLECULAR PATHOLOGY; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMIC PROFILING; PROTEOMICS; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR CELL; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

DIAGNOSIS, DIFFERENTIAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; PREDICTIVE VALUE OF TESTS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VALIDATION STUDIES AS TOPIC;

EID: 84859399300     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0856     Document Type: Article

References (59)

1. Tumours of the thyroid and parathyroid. In WHO Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs, pp 49-133. Eds RA DeLellis, RV Lloyd, PU Heitz & C Eng. Lyon: IARC Press, 2004.
2. Damante G, Scaloni A & Tell G. Thyroid tumors: novel insights from proteomic studies. Expert Review of Proteomics 2009 6 363-376. (doi:10.1586/epr.09.51)
3. Lui WO, Zeng L, Rehrmann V, Deshpande S, Tretiakova M, Kaplan EL, Leibiger I, Leibiger B, Enberg U, Hoog A, Larsson C &Kroll TG. CREB3L2-PPARgamma fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis. Cancer Research 2008 68 7156-7164. (doi:10.1158/0008-5472.CAN-08-1085)
4. Nikiforova MN & Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Review of Molecular Diagnostics 2008 8 83-95. (doi:10.1586/14737159.8.1.83)
5. Barden CB, Shister KW, Zhu B, Guiter G, Greenblatt DY, Zeiger MA & Fahey TJ III. Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clinical Cancer Research 2003 9 1792-1800. (Pubitemid 36554606)
6. Finley DJ, Zhu B, Barden CB & Fahey TJ III. Discrimination of benign and malignant thyroid nodules by molecular profiling. Annals of Surgery 2004 240 425-436 discussion 436-427. (doi:10.1097/01.sla.0000137128.64978.bc)
7. Mazzanti C, Zeiger MA, Costouros NG, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR & Libutti SK. Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Research 2004 64 2898-2903. (doi:10.1158/0008-5472.CAN-03-3811)
8. Lui WO, Foukakis T, Liden J, Thoppe SR, Dwight T, Hoog A, Zedenius J, Wallin G, Reimers M & Larsson C. Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPAR(gamma) fusion oncogene. Oncogene 2005 24 1467-1476. (doi:10.1038/sj.onc.1208135)
9. Wilkins MR, Pasquali C, Appel RD, Ou K, Golaz O, Sanchez JC, Yan JX, Gooley AA, Hughes G, Humphery-Smith I, Williams KL & Hochstrasser DF. From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology 1996 14 61-65. (doi:10.1038/nbt0196-61)
10. de Hoog CL & Mann M. Proteomics. Annual Review of Genomics and Human Genetics 2004 5 267-293. (doi:10.1146/annurev.genom.4.070802.110305)
11. Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, Doyle MJ, Yi EC, Dai H, Thorsson V, Eng J, Goodlett D, Berger JP, Gunter B, Linseley PS, Stoughton RB, Aebersold R, Collins SJ, Hanlon WA &Hood LE. Integrated genomic and proteomic analyses of gene expression in mammalian cells. Molecular & Cellular Proteomics 2004 3 960-969. (doi:10.1074/mcp.M400055-MCP200)
12. de Godoy LM, Olsen JV, Cox J, Nielsen ML, Hubner NC, Frohlich F, Walther TC & Mann M. Comprehensive mass-spectrometry-based proteome quantification of haploid versus diploid yeast. Nature 2008 455 1251-1254. (doi:10.1038/ nature07341)
13. Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, Heinz DE, Shroyer KR, Duncan MW & Haugen BR. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Molecular Carcinogenesis 2006 45 613-626. (doi:10.1002/mc.20193)
14. Krause K, Karger S, Schierhorn A, Poncin S, Many MC & Fuhrer D. Proteomic profiling of cold thyroid nodules. Endocrinology 2007 148 1754-1763. (doi:10.1210/en.2006-0752)
15. Moretz WH III, Gourin CG, Terris DJ, Xia ZS, Liu Z, Weinberger PM, Chin E & Adam BL. Detection of papillary thyroid carcinoma with serum protein profile analysis. Archives of Otolaryngology - Head & Neck Surgery 2008 134 198-202. (doi:10.1001/archoto.2007.34)
16. Netea-Maier RT, Hunsucker SW, Hoevenaars BM, Helmke SM, Slootweg PJ, Hermus AR, Haugen BR & Duncan MW. Discovery and validation of protein abundance differences between follicular thyroid neoplasms. Cancer Research 2008 68 1572-1580. (doi:10.1158/0008-5472.CAN-07-5020)
17. Wang JX, Yu JK, Wang L, Liu QL, Zhang J & Zheng S. Application of serum protein fingerprint in diagnosis of papillary thyroid carcinoma. Proteomics 2006 6 5344-5349. (doi:10.1002/pmic.200500833)
18. Krause K, Jessnitzer B & Fuhrer D. Proteomics in thyroid tumor research. Journal of Clinical Endocrinology and Metabolism 2009 94 2717-2724. (doi:10.1210/jc.2009-0308)
19. 2+-binding protein S100A6 in papillary thyroid carcinoma. Thyroid 2010 20 1067-1076. (doi:10.1089/thy.2009.0400)
20. Forsberg L, Larsson C, Sofiadis A, Lewensohn R, Hoog A & Lehtio J. Pre-fractionation of archival frozen tumours for proteomics applications. Journal of Biotechnology 2006 126 582-586. (doi:10.1016/j.jbiotec.2006.05.020)
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 1976 72 248-254. (doi:10.1016/0003-2697(76)90527-3)
22. Hellman K, Alaiya AA, Becker S, Lomnytska M, Schedvins K, Steinberg W, Hellstrom AC, Andersson S, Hellman U & Auer G. Differential tissue-specific protein markers of vaginal carcinoma. British Journal of Cancer 2009 100 1303-1314. (doi:10.1038/sj.bjc.6604975)
23. Rabilloud T, Vuillard L, Gilly C & Lawrence JJ. Silver-staining of proteins in polyacrylamide gels: a general overview. Cellular and Molecular Biology 1994 40 57-75.
24. Wold S, Esbensen K & Geladi P. Principal component analysis. Chemometrics and Intelligent Laboratory Systems 1987 2 37-52. (doi:10.1016/0169-7439(87)80084-9)
25. Benjamini Y & Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B, Statistical Methodology 1995 57 289-300.
26. Geladi P & Kowalski B. Partial least-squares regression - a tutorial. Analytica Chimica Acta 1986 185 1-17. (doi:10.1016/0003-2670(86)80028-9)
27. Wold S, Sjöstrom M & Eriksson L. PLS-regression: a basic tool of chemometrics. Chemometrics and Intelligent Laboratory Systems 2001 58 109-130. (doi:10.1016/S0169-7439(01)00155-1)
28. Wold S, Johansson E & Gocchi M. PLS - partial least-squares projections to latent structures. In 3D QSAR in Drug Design; Theory, Methods and Applications, pp 523-550. Ed HK Dordrecht. The Netherlands: Kluwer Academic Publishers, 1993.
29. Efron B. Estimating the error rate of a prediction rule - improvement on cross-validation. Journal of the American Statistical Association 1983 78 316-331. (doi:10.2307/2288636)
30. Krause K, Schierhorn A, Sinz A, Wissmann JD, Beck-Sickinger AG, Paschke R & Fuhrer D. Toward the application of proteomics to human thyroid tissue. Thyroid 2006 16 1131-1143. (doi:10.1089/thy.2006.16.1131)
31. Petrak J, Ivanek R, Toman O, Cmejla R, Cmejlova J, Vyoral D, Zivny J & Vulpe CD. Deja vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. Proteomics 2008 8 1744-1749. (doi:10.1002/pmic.200700919)
32. Srisomsap C, Subhasitanont P, Otto A, Mueller EC, Punyarit P, Wittmann-Liebold B & Svasti J. Detection of cathepsin B up-regulation in neoplastic thyroid tissues by proteomic analysis. Proteomics 2002 2 706-712. (doi:10.1002/1615-9861(200206)2:6〈706::AID-PROT706〉3.0.CO;2-E)
33. Giusti L, Iacconi P, Ciregia F, Giannaccini G, Donatini GL, Basolo F, Miccoli P, Pinchera A & Lucacchini A. Fine-needle aspiration of thyroid nodules: proteomic analysis to identify cancer biomarkers. Journal of Proteome Research 2008 7 4079-4088. (doi:10.1021/pr8000404)
34. Morrison DK. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends in Cell Biology 2009 19 16-23. (doi:10.1016/j.tcb.2008.10.003)
35. Ito Y, Yoshida H, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Nakamura Y, Kakudo K, Kuma K &Miyauchi A. Caveolin-1 and 14-3-3 sigma expression in follicular variant of thyroid papillary carcinoma. Pathology, Research and Practice 2005 201 545-549. (doi:10.1016/j.prp.2005.08. 002)
36. Ito Y, Miyoshi E, Uda E, Yoshida H, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Matsuura N, Kakudo K, Kuma K &Miyauchi A. 14-3-3 Sigma possibly plays a constitutive role in papillary carcinoma, but not in follicular tumor of the thyroid. Cancer Letters 2003 200 161-166. (doi:10.1016/S0304-3835(03)00282-9)
37. Lal G, Padmanabha L, Provenzano M, Fitzgerald M, Weydert J &Domann FE. Regulation of 14-3-3sigma expression in human thyroid carcinoma is epigenetically regulated by aberrant cytosine methylation. Cancer Letters 2008 267 165-174. (doi:10.1016/j.canlet.2008.03.017)
38. Blankenberg FG. In vivo detection of apoptosis. Journal of Nuclear Medicine 2008 49 (Suppl 2) 81S-95S. (doi:10.2967/jnumed.107.045898)
39. Alfonso P, Canamero M, Fernandez-Carbonie F, Nunez A & Casal JI. Proteome analysis of membrane fractions in colorectal carcinomas by using 2D-DIGE saturation labeling. Journal of Proteome Research 2008 7 4247-4255. (doi:10.1021/pr800152u)
40. Srisomsap C, Sawangareetrakul P, Subhasitanont P, Chokchaichamnankit D, Chiablaem K, Bhudhisawasdi V, Wongkham S & Svasti J. Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes. Journal of Biomedicine & Biotechnology 2010 2010 437143. (doi:10.1155/2010/437143)
41. Thongwatchara P, Promwikorn W, Srisomsap C, Chokchaichamnankit D, Boonyaphiphat P & Thongsuksai P. Differential protein expression in primary breast cancer and matched axillary node metastasis. Oncology Reports 2012 26 185-191. (doi:10.3892/or.2011.1266)
42. Chang PW, Tsui SK, Liew C, Lee CC, Waye MM & Fung KP. Isolation, characterization, and chromosomal mapping of a novel cDNA clone encoding human selenium binding protein. Journal of Cellular Biochemistry 1997 64 217-224. (doi:10.1002/(SICI)1097-4644(199702)64:2〈217::AID-JCB5〉3.0.CO;2-)
43. Papp LV, Lu J, Holmgren A & Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxidants & Redox Signaling 2007 9 775-806. (doi:10.1089/ars.2007.1528)
44. Chen G, Wang H, Miller CT, Thomas DG, Gharib TG, Misek DE, Giordano TJ, Orringer MB, Hanash SM & Beer DG. Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. Journal of Pathology 2004 202 321-329. (doi:10.1002/path.1524)
45. Li LS, Kim H, Rhee H, Kim SH, Shin DH, Chung KY, Park KS, Paik YK & Chang J. Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of nonsmall cell lung carcinoma. Proteomics 2004 4 3394-3400. (doi:10.1002/pmic.200400901)
46. Kim H, Kang HJ, You KT, Kim SH, Lee KY, Kim TI, Kim C, Song SY, Kim HJ & Lee C. Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics 2006 6 3466-3476. (doi:10.1002/pmic.200500629)
47. Huang KC, Park DC, Ng SK, Lee JY, Ni X, Ng WC, Bandera CA, Welch WR, Berkowitz RS, Mok SC & Ng SW. Selenium binding protein 1 in ovarian cancer. International Journal of Cancer 2006 118 2433-2440. (doi:10.1002/ijc.21671)
48. He QY, Cheung YH, Leung SY, Yuen ST, Chu KM & Chiu JF. Diverse proteomic alterations in gastric adenocarcinoma. Proteomics 2004 4 3276-3287. (doi:10.1002/pmic.200300916)
49. Silvers AL, Lin L, Bass AJ, Chen G, Wang Z, Thomas DG, Lin J, Giordano TJ, Orringer MB, Beer DG & Chang AC. Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity. Clinical Cancer Research 2010 16 2009-2021. (doi:10.1158/1078-0432.CCR-09-2801)
50. Zhang B, Wang Y & Su Y. Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Letters 2009 286 154-160. (doi:10.1016/j.canlet.2009.04. 043)
51. Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG & Soini Y. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. Journal of Pathology 2002 196 316-323. (doi:10.1002/path.1042)
52. Fujita Y, Nakanishi T, Hiramatsu M, Mabuchi H, Miyamoto Y, Miyamoto A, Shimizu A & Tanigawa N. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clinical Cancer Research 2006 12 6415-6420. (doi:10.1158/1078-0432. CCR-06-1315)
53. Park CK, Kim JH, Moon MJ, Jung JH, Lim SY, Park SH, Kim DG, Jung HW, Cho BK & Paek SH. Investigation of molecular factors associated with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression. Journal of Cancer Research and Clinical Oncology 2008 134 255-262. (doi:10.1007/s00432-007-0282-1)
54. Karihtala P, Mantyniemi A, Kang SW, Kinnula VL & Soini Y. Peroxiredoxins in breast carcinoma. Clinical Cancer Research 2003 9 3418-3424. (Pubitemid 37082738)
55. Gerard AC, Many MC, Daumerie C, Knoops B & Colin IM. Peroxiredoxin 5 expression in the human thyroid gland. Thyroid 2005 15 205-209. (doi:10.1089/thy.2005.15.205)
56. Yanagawa T, Ishikawa T, Ishii T, Tabuchi K, Iwasa S, Bannai S, Omura K, Suzuki H & Yoshida H. Peroxiredoxin I expression in human thyroid tumors. Cancer Letters 1999 145 127-132. (doi:10.1016/S0304-3835(99)00243-8)
57. Kivirikko KI & Myllyharju J. Prolyl 4-hydroxylases and their protein disulfide isomerase subunit. Matrix Biology 1998 16 357-368. (doi:10.1016/S0945-053X(98)90009-9)
58. Poon E, Harris AL & Ashcroft M. Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Reviews in Molecular Medicine 2009 11 e26. (doi:10.1017/S1462399409001173)
59. Myllyharju J. Prolyl 4-hydroxylases, key enzymes in the synthesis of collagens and regulation of the response to hypoxia, and their roles as treatment targets. Annals of Medicine 2008 40 402-417. (doi:10.1080/ 07853890801986594)